FDA to Decide on Three Drug Applications

Regulators are set to rule this week on Summit's Ivonescimab, Cytokinetics' Myqorzo label expansion, and Igalmi's at-home use.

Updated on Nov. 9, 2026 in Healthcare

FDA to Decide on Three Drug Applications

Live Poll

Do you trust new prescription drugs to deliver the benefits they promise?

The FDA is expected to announce decisions this week on three drug applications from Summit Therapeutics, Cytokinetics and Teva. The rulings come as the companies report Phase 3 trial results and Teva expands its neurology portfolio.

Why it matters

The decisions will determine whether newly tested cancer and heart therapies can expand their approved uses in the United States. Investors and patients are watching closely as the companies' stock prices have moved sharply this year.

Teva paid $57.5 million upfront for worldwide Igalmi rights, with up to $67.5 million more tied to FDA approval for BioXcel's estate. Teva's stock is up 36.7% this year, while Cytokinetics is down 13% and Summit is down 6.8%.

The players

U.S. Food and Drug Administration

The federal agency responsible for regulating and approving drugs and medical products sold in the United States.

Summit Therapeutics

A biopharmaceutical company developing Ivonescimab, a bispecific antibody designed to block the PD-1 and VEGF proteins.

Cytokinetics

A biopharmaceutical company focused on cardiovascular therapies, including its heart drug Myqorzo.

Teva Pharmaceuticals

A global generic and specialty drugmaker that acquired worldwide rights to Igalmi this year.

The details

Summit's Phase 3 Harmoni trial met its primary goal of improving progression-free survival, though its initial analysis did not show a statistically significant overall survival benefit; updated results showed a 24% estimated reduction in death risk. Cytokinetics' Phase 3 Maple-HCM trial found patients on Myqorzo improved exercise capacity more than those on metoprolol after 24 weeks. Teva acquired worldwide rights to Igalmi from BioXcel Therapeutics last month.

Last month: Teva acquired worldwide rights to Igalmi from BioXcel Therapeutics.
Last week: Summit reported updated Harmoni survival results.
This week: The FDA is expected to announce decisions on Ivonescimab, Myqorzo and Igalmi.
This month: The FDA is expected to decide on Capricor's Deramiocel.

Healthcare Landscape

Regulators' willingness to approve drugs on progression-free survival gains, as the FDA has done under its oncology accelerated approval pathways, is being tested by Ivonescimab's mixed survival data. The decision will shape how biotech companies design late-stage trials for cancer and cardiac therapies.

If approved, Myqorzo and Ivonescimab would give patients new options for heart and cancer treatment in the United States. Igalmi's at-home use would mean patients could potentially be treated outside a clinical setting, subject to FDA approval.

The takeaway

Regulatory decisions this week on three drugs could change treatment options for cancer and heart patients in the United States. Investors should watch whether the FDA accepts progression-free survival gains without statistically significant overall survival benefits.

What happens next

The FDA is expected to announce its verdicts on Ivonescimab, Myqorzo's label expansion and Igalmi's at-home expansion this week, with Capricor's Deramiocel decision due this month.